SRRK

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of medicines for the treatment of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. The Company’s product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGFb1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. The Company is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGFb1 in the context of fibrotic extracellular matrix and that avoid perturbing TGFb1 presented by cells of the immune system.